# Phase IIB TL + YCWP + DC in Melanoma

> **NCT02301611** · PHASE2 · COMPLETED · sponsor: **Elios Therapeutics, LLC** · enrollment: 187 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** TLPLDC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02301611
- **Lead sponsor:** Elios Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2022-05-11
- **Final completion:** 2022-05-11
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2024-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02301611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02301611, "Phase IIB TL + YCWP + DC in Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02301611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*